Biomarkers For Enhanced Vaccine Safety (BioVacSafe)

On March 1st 2012 the IMI-JU funded project – Biomarkers for Enhanced Vaccine Safety (BioVacSafe) – initiated its collaborative work to develop new tools that will improve the evaluation and monitoring of vaccine immunosafety. BioVacSafe is a public private consortium of 19 partners involving three of Europe's leading vaccine producing companies, experts from major academic institutions, small and medium-sized enterprises (SMEs) and non-governmental organization (NGO) actors. The total budget of the project is 30.2 millions of Euros and it will last for five years. BioVacSafe aims at establishing tools, methods and guidelines for the evaluation of vaccine reactogenicity and enhancing immunosafety of novel vaccines. In that context, BioVacSafe partners have a unique opportunity to tackle the urgent need to establish new ways of collaboration among industry, academia, biotech companies, regulators and patients' organizations to promote and support R&D for safer vaccines

Participants

Jens B Nielsen (contact)

Avdelningschef vid Chalmers, Biology and Biological Engineering

Collaborations

CDISC European Foundation

Woluwe-Saint Lambert, Belgium

Charité University Medicine Berlin

Berlin, Germany

Department Of Health

Leeds, United Kingdom

Ghent university

Gent, Belgium

GlaxoSmithKline Biologicals - Belgium

Rixensart, Belgium

ImmunArray

Rehovot, Israel

Imperial College London

London, United Kingdom

Max-Planck-Gesellschaft, Berlin

Berlin, Germany

Novartis Vaccines & Diagnostics

Siena, Italy

Sanofi Pasteur

Lyon, France

St George's Univerity of London

London, United Kingdom

Statens Serum Institut

Köpenhamn, Denmark

The French Alternative Energies and Atomic Energy Commission (CEA)

Grenoble Cedex 09, France

University of Gothenburg

Gothenburg, Sweden

University of Siena

Siena, Italy

University of Surrey

Surrey, United Kingdom

Utrecht University

Utrecht, Netherlands

VisMederi

Siena, Italy

Funding

European Commission (EC)

Funding Chalmers participation during 2012–2017

More information

Project Web Page

www.biovacsafe.eu

Latest update

2016-12-15